-
公开(公告)号：US08765663B2
公开(公告)日：2014-07-01
申请号：US13404593
申请日：2012-02-24
IPC分类号： A61K38/00 , A61K39/00 , A61K39/395
CPC分类号： C07K16/40 , A61K31/00 , A61K31/7088 , A61K38/179 , A61K2039/505 , C07K14/705 , C07K16/22 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/30
摘要： In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.
摘要翻译： 在某些方面，本发明提供了通过施用ActRIIB信号通路的拮抗剂来增加有需要的患者中的脂连蛋白的组合物和方法。 此类拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗激活素A和/或B抗体，抗肌生成抑制素抗体，抗GDF3抗体和抗BMP7抗体。 还提供了用于改善一种或多种不期望的抗雄激素治疗效果的方法，包括肌肉损失，骨丢失，增加的肥胖和/或增加的胰岛素抵抗。 可以通过引起循环中脂联素浓度的增加来治疗多种疾病。
-
公开(公告)号：US20100183624A1
公开(公告)日：2010-07-22
申请号：US12657146
申请日：2010-01-13
IPC分类号： A61K38/02 , A61K39/395 , A61K31/7088 , A61P5/00 , A61P3/10
CPC分类号： C07K16/40 , A61K31/00 , A61K31/7088 , A61K38/179 , A61K2039/505 , C07K14/705 , C07K16/22 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/30
摘要： In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.
摘要翻译： 在某些方面，本发明提供了通过施用ActRIIB信号通路的拮抗剂来增加有需要的患者中的脂连蛋白的组合物和方法。 此类拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗激活素A和/或B抗体，抗肌生成抑制素抗体，抗GDF3抗体和抗BMP7抗体。 还提供了用于改善一种或多种不期望的抗雄激素治疗效果的方法，包括肌肉损失，骨丢失，增加的肥胖和/或增加的胰岛素抵抗。 可以通过引起循环中脂联素浓度的增加来治疗多种疾病。
-
公开(公告)号：US20120156204A1
公开(公告)日：2012-06-21
申请号：US13404593
申请日：2012-02-24
CPC分类号： C07K16/40 , A61K31/00 , A61K31/7088 , A61K38/179 , A61K2039/505 , C07K14/705 , C07K16/22 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/30
摘要： In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.
摘要翻译： 在某些方面，本发明提供了通过施用ActRIIB信号通路的拮抗剂来增加有需要的患者中的脂连蛋白的组合物和方法。 此类拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗激活素A和/或B抗体，抗肌生成抑制素抗体，抗GDF3抗体和抗BMP7抗体。 还提供了用于改善一种或多种不期望的抗雄激素治疗效果的方法，包括肌肉损失，骨丢失，增加的肥胖和/或增加的胰岛素抵抗。 可以通过引起循环中脂联素浓度的增加来治疗多种疾病。
-
公开(公告)号：US08138142B2
公开(公告)日：2012-03-20
申请号：US12657146
申请日：2010-01-13
CPC分类号： C07K16/40 , A61K31/00 , A61K31/7088 , A61K38/179 , A61K2039/505 , C07K14/705 , C07K16/22 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/30
摘要： In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.
摘要翻译： 在某些方面，本发明提供了通过施用ActRIIB信号通路的拮抗剂来增加有需要的患者中的脂连蛋白的组合物和方法。 此类拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗激活素A和/或B抗体，抗肌生成抑制素抗体，抗GDF3抗体和抗BMP7抗体。 还提供了用于改善一种或多种不期望的抗雄激素治疗效果的方法，包括肌肉损失，骨丢失，增加的肥胖和/或增加的胰岛素抵抗。 可以通过引起循环中脂联素浓度的增加来治疗多种疾病。
-
公开(公告)号：US08722615B2
公开(公告)日：2014-05-13
申请号：US12959220
申请日：2010-12-02
申请人： Jasbir Seehra , John Knopf , Ravindra Kumar
发明人： Jasbir Seehra , John Knopf , Ravindra Kumar
IPC分类号： A61K38/00
CPC分类号： C07K14/7151 , A61K38/00 , C07K16/00 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
-
公开(公告)号：US08293881B2
公开(公告)日：2012-10-23
申请号：US12796307
申请日：2010-06-08
申请人： Jasbir Seehra , Ravindra Kumar
发明人： Jasbir Seehra , Ravindra Kumar
CPC分类号： C12N9/12 , A61K38/00 , C07K14/475 , C07K14/71 , C07K2319/30 , C12N2510/02 , C12Y207/1103
摘要： In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
摘要翻译： 在某些方面，本发明提供了用于调节（促进或抑制）组织如骨，软骨，肌肉，脂肪，棕色脂肪和/或神经元组织的生长并用于治疗代谢性疾病如糖尿病和肥胖的组合物和方法 ，以及与任何前述组织相关的疾病。
-
公开(公告)号：US20120148588A1
公开(公告)日：2012-06-14
申请号：US13403657
申请日：2012-02-23
申请人： John Knopf , Jasbir Seehra , Ravindra Kumar
发明人： John Knopf , Jasbir Seehra , Ravindra Kumar
IPC分类号： A61K39/395 , A61P21/00 , A61P3/00
CPC分类号： C07K16/40 , A61K31/7088 , A61K38/00 , A61K38/1796 , A61P3/00 , A61P3/04 , A61P3/10 , A61P21/00 , C07K14/71 , C07K2319/30 , C12N5/0602
摘要： In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF 11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
摘要翻译： 在某些方面，本发明提供通过施用ActRIIB信号传导途径的拮抗剂来增加产热脂肪细胞（例如，棕色脂肪细胞或其他表达UCP-1的脂肪细胞）的组合物和方法。 这些拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗肌生成抑制素抗体，抗GDF3抗体，抗-Nodal，抗激活素和抗GDF11抗体。 可以通过引起生热脂肪细胞的增加来治疗各种代谢和其它疾病。
-
公开(公告)号：US20110171218A1
公开(公告)日：2011-07-14
申请号：US12959220
申请日：2010-12-02
申请人： Jasbir Seehra , John Knopf , Ravindra Kumar
发明人： Jasbir Seehra , John Knopf , Ravindra Kumar
IPC分类号： A61K39/395 , C07H21/00 , C12P21/00 , C12N5/10 , C07K19/00 , A61P29/00 , A61P37/06 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P33/00 , A61P25/28 , A61P25/16 , C12N1/00
CPC分类号： C07K14/7151 , A61K38/00 , C07K16/00 , C07K2317/94 , C07K2319/00 , C07K2319/30
摘要： Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
摘要翻译： 本文提供了具有增加的血清半衰期的糖型变异Fc融合蛋白。 还提供了通过引入一个或多个非内源糖基化位点来增加Fc融合蛋白的血清半衰期的方法。
-
公开(公告)号：US20100160225A1
公开(公告)日：2010-06-24
申请号：US12586207
申请日：2009-09-18
申请人： John Knopf , Jasbir Seehra , Ravindra Kumar
发明人： John Knopf , Jasbir Seehra , Ravindra Kumar
IPC分类号： A61K38/16 , C07K14/435 , C07K16/00 , C12N15/12 , C12N5/16 , C12N5/22 , C12P21/00 , A61P21/00 , A61P3/04 , A61P25/00 , A61P29/00 , A61P9/00 , A61P9/12 , A61P11/00
CPC分类号： C07K14/47 , A61K38/00 , C07K14/495
摘要： The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.
摘要翻译： 本公开涉及Lefty衍生物和Lef多肽作为某些配体如Nodal，GDF-8（Myostatin）和GDF-11功能的拮抗剂的用途。 这些衍生物可以与其它功能异源蛋白如IgG，特别是IgG的Fc部分融合。 根据该公开内容，Lefty多肽可用于治疗各种疾病，包括例如神经元疾病，肌肉和骨骼状况以及代谢紊乱。
-
公开(公告)号：US20080175844A1
公开(公告)日：2008-07-24
申请号：US11982738
申请日：2007-11-02
CPC分类号： A61K39/39558 , A61K45/06 , C07K14/71 , C07K16/18 , C07K2317/52 , C07K2319/30
摘要： In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
摘要翻译： 在某些方面，本公开涉及以下认识：包含活化素样激酶I（ALK1）多肽的细胞外结构域的配体结合部分的多肽可用于抑制体内血管发生，特别是在血管生成相关的哺乳动物中 疾病 该公开内容还鉴定了ALK1的配体，并证明这些配体具有促血管生成活性，以及抑制受体 - 配体相互作用的抗体。
-
-
-
-
-
-
-
-
-
搜索结果
90 条记录 (耗时 0.051 秒)
